Global Longevity Intelligence
LongevityNext connects source-reviewed Explainers and structured dossiers without collapsing biological activity, clinical evidence, commercial claims or regulatory context into one score.
Source-reviewed intelligence
Start with the strongest current source-reviewed records.
Evidence reviewed
A role-based framework for reading trial endpoints, estimands, multiplicity, clinical meaning and surrogate claims.
Boundary: Endpoint labels alone do not establish confirmatory force or clinical importance.
Evidence reviewed
A claim-to-evidence framework separating exposure, target engagement, biomarker movement, safety and clinical benefit.
Boundary: Interpretive context does not establish that an intervention works.
Evidence reviewed
The aging Hallmarks are an influential research framework, not a complete causal theory, treatment checklist or validated endpoint set.
Boundary: Framework context does not validate an intervention, biomarker or clinical endpoint.
Source-reviewed intelligence
Evidence dates show when each record’s bounded source set was last reviewed.
Evidence reviewed
Research-stage DNA methylation age and pace-of-aging measures with bounded utility claims.
Boundary: Does not establish diagnosis, clinical utility or a definitive biological-age reading.
Evidence reviewed
A cautious source-backed review of clinic advertising and regenerative-medicine claim-risk patterns.
Boundary: Not legal advice or a clinic-specific legal conclusion.
Evidence reviewed
Regulatory claim-risk context for consumer biomarkers and direct-to-consumer tests.
Boundary: Not legal advice, biological evidence or a product-specific finding.
Source-reviewed intelligence
Structured dossiers and claims-watch records retain their type, review date and evidence boundary.
Evidence reviewed
A small randomized crossover mechanistic study in older adults with impaired glucose tolerance.
Boundary: Not clinical longevity-outcome, treatment, prevention or dosing evidence.
Evidence reviewed
Company-and-pipeline intelligence separating company reports, registry facts and unavailable clinical outcomes.
Boundary: Pipeline and source mapping, not clinical validation or investment analysis.
Evidence reviewed
Distinct immune-aging model families mapped as research-stage signals with explicit validation gaps.
Boundary: Not an approved diagnostic, consumer test, surrogate endpoint or clinical decision tool.
Explore by section
Sections appear here when current source-reviewed coverage is strong enough to be useful.
Methodology
LN Pro preview
Future professional workflows may include saved trackers, monitored updates and analyst-oriented views. LN Pro is not represented here as a live product.
Request accessPublic updates